The U.K.’s National Institute for Health and Clinical and Clinical Excellence has agreed to support reimbursement for Eli Lilly & Co.'s Efient (prasugrel) for acute coronary syndrome – a widening of a currently restricted label – even though Lilly declined NICE’s recommendation to compare the drug with AstraZeneca PLC's Brilinta.
Generally, a manufacturer’s decision not to compare its product with another selected by a European health technology assessment agency such...